title: Mixing rapid-acting insulin analogues with insulin glargine in children with type 1 diabetes mellitus.
abstract: OBJECTIVE
  To determine whether mixing insulin glargine (IG) with a rapid-acting insulin (RAI) analogue in the same syringe had any deleterious effects on glycemic control in children with type 1 diabetes mellitus.
  
  
  METHODS
  Data from 55 children mixing the IG with a RAI analogue was collected for 6 months before and 6 months after the insulin mixing began. Data from a control group of 55 children not mixing the insulins was collected at similar intervals. Parameters evaluated included hemoglobin A1c (HbA1c) values, number of non-severe and severe hypoglycemic events, number of diabetic ketoacidosis (DKA) events, and blood glucose distribution patterns.
  
  
  RESULTS
  After 6 months of study, HbA1c values were equivalent for the control and test groups (8.54+/-1.14 vs 8.61+/-1.14, respectively; P=1.0000). Percentages of blood glucose values in, above, and below the target range did not vary significantly in the groups. There were no significant differences in the groups in the occurrence of non-severe or severe hypoglycemic events or of DKA events.
  
  
  CONCLUSIONS
  There were no significant differences in glycemic control between children who mixed IG in the same syringe with a RAI analogue compared with children who took separate injections.
authors.affiliation: Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, Colorado, USA. rosanna.fiallo-scharer@uchsc.edu
authors.forename: Rosanna
authors.initials: R
authors.lastname: Fiallo-Scharer
authors.forename: Brian
authors.initials: B
authors.lastname: Horner
authors.forename: Kim
authors.initials: K
authors.lastname: McFann
authors.forename: Philippe
authors.initials: P
authors.lastname: Walravens
authors.forename: H Peter
authors.initials: HP
authors.lastname: Chase
mesh_terms: D000293:Adolescent; D002648:Child; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D016883:Diabetic Ketoacidosis / Q000139:chemically induced; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007267:Injections; D007328:Insulin / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives*; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D008297:Male; D016555:Matched-Pair Analysis; D010349:Patient Compliance; D011446:Prospective Studies; D012044:Regression Analysis
chemical_list: D004338:Drug Combinations; D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine